A randomized, open-label study of 800 mg lopinavir/200 mg ritonavir QD [once daily] in combination with tenofovir [disoproxil fumarate] and emtricitabine vs. 400 mg lopinavir/100 mg ritonavir bid [twice daily] in combination with tenofovir and emtricitabine in HIV-infected antiretroviral naive subjects
Latest Information Update: 07 Dec 2006
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine; Tenofovir disoproxil fumarate
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 07 Dec 2006 New trial record.